Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.

Terufumi KawamotoNaoto ShikamaNobuki ImanoHikaru KubotaTakashi KosugiShuhei SekiiHideyuki HaradaKazunari YamadaYutaka NaoiKazunari MiyazawaYasuhiro HiranoYuki WadaAyako TonariTetsuo SaitoNobue UchidaNorio ArakiNaoki Nakamura

Published in: Breast cancer (Tokyo, Japan) (2022)

Moderate toxicities are frequent with combined RT and CDK4/6i. Caution is necessary concerning the combined RT and CDK4/6i. Particularly, reducing the dose to normal organs is necessary for combined RT and CDK4/6i.

Keyphrases

cell cycle
metastatic breast cancer
early stage
oxidative stress
radiation therapy
risk factors
locally advanced
rectal cancer